Kiniksa Pharmaceuticals International (KNSA) Shares Outstanding (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 10 years of Shares Outstanding (Entity) data on file, last reported at $78.0 million in Q2 2026.

• Quarterly Shares Outstanding (Entity) rose 5.33% year-over-year to $78.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $78.0 million (up 5.33% YoY) and the FY2025 annual result came in at $76.3 million, up 5.21% from the prior year.
• Shares Outstanding (Entity) grew to $78.0 million in Q2 2026, from $76.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $78.0 million in Q2 2026 to a low of $69.3 million in Q1 2022.
• A 5-year average of $72.1 million and a median of $71.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) grew 0.81% — and 2026, when it rose 5.35%.
• Tracing KNSA's Shares Outstanding (Entity) over 5 years: stood at $69.7 million in 2022, then advanced by 1.09% to $70.5 million in 2023, then increased by 2.92% to $72.5 million in 2024, then rose by 5.21% to $76.3 million in 2025, then increased by 2.21% to $78.0 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $78.0 million (Q2 2026), $76.7 million (Q1 2026), and $76.3 million (Q4 2025), per Business Quant data.